In a broad-ranging slate of tech collaborations, AstraZeneca is allying itself with several top research institutions to hone its ability to apply CRISPR gene editing techniques to its drug development work. And the pharma giant used this alliance to pick some of the best brains in the business, without turning to any of the pioneers who have recently spawned a lineup of upstart biotechs.
Box has added a big-name client just days after pulling off a $175 million IPO. The deal sees AstraZeneca join Allergan and Eli Lilly on the list of major biopharma companies that use Box's cloud content sharing and collaboration tools.
AstraZeneca's gout treatment lesinurad may have a checkered efficacy record, but the European Medicines Agency has accepted the company's application for the drug--meaning it still has a chance to become the blockbuster the British pharma giant had hoped for.
The European Medicines Agency has accepted AstraZeneca's application for lesinurad, a gout treatment with a checkered efficacy record, stoking the company's hopes that it can make the drug into a blockbuster.
Soon after CEO Pascal Soriot took over at AstraZeneca in 2012, he declared Brilinta to be a big opportunity for growth. That was a surprise, given the blood thinner's laggardly sales since its 2011 launch. But Soriot put cash on the table to back up his hunch, with plans for big outcomes studies, stepped-up advertising, and an expanded cadre of sales reps.
AstraZeneca won accelerated FDA approval for its ovarian cancer fighter Lynparza (olaparib), opening the door for potential blockbuster sales of the drug and helping the company distinguish itself from rivals in the BRCA playing field.
In one interview published over the weekend, AstraZeneca CEO Pascal Soriot pooh-poohed the idea of Pfizer coming back with another takeover bid. In another, he gave a subtle warning about his company's stated goal of hitting $45 billion in sales within a decade.
Despite loud objections from its advisers, the FDA granted an accelerated approval to AstraZeneca's ovarian cancer treatment, clearing an oral therapy the U.K. drugmaker believes will bring in blockbuster sales.
AstraZeneca scored European approval for its ovarian cancer-treating drug Lynparza (olaparib), expanding its cancer portfolio at a time when the company is trying to show investors that it's better off independent.
Just a week after saying it would close a plant in the U.S. and whack 180 jobs, AstraZeneca said that a facility in the U.K. will also close and 250 more jobs will be cut there.